Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
Rhea-AI Summary
Biodexa Pharmaceuticals (NASDAQ:BDRX) has received FDA Fast Track status for eRapa, its drug treating familial adenomatous polyposis (FAP), following positive Phase 2 results and Orphan Drug designation. The Phase 2 trial showed promising results with a 17% median decrease in overall polyp burden and 75% non-progression rate. Notably, cohort 2 demonstrated an 89% non-progression rate and 29% median reduction in polyp burden at 12 months.
FAP is an inherited condition affecting 1 in 5,000-10,000 people in the U.S. and 1 in 11,300-37,600 in Europe, leading to a nearly 100% lifetime risk of colorectal cancer. Currently, there are no approved therapeutic options, with surgery being the standard treatment. The upcoming Phase 3 study will be double-blind placebo-controlled, recruiting approximately 168 high-risk FAP patients.
Positive
- FDA Fast Track designation received for eRapa
- Phase 2 trial showed 17% median decrease in polyp burden
- Cohort 2 achieved 89% non-progression rate
- Patent protection extends through 2035
- Large market potential with up to 40,000 U.S. and 60,000 European patients
Negative
- Phase 3 trials still required for approval
- Current lack of approved therapeutic options indicates challenging regulatory pathway
News Market Reaction – BDRX
On the day this news was published, BDRX declined 2.83%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). The news follows Biodexa reporting positive 12-month data from a phase 2 clinical trial in July 2024, as previously covered by Benzinga.
The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions where there is an unmet medical need. FAP, an inherited condition that puts people at a much greater risk of developing colon cancer, falls into that category. The condition is typically diagnosed in the early teenage years and results in a nearly
To be considered a "serious" disease by the FDA, a condition must have a substantial impact on survival and daily functioning or the likelihood that it will worsen over time if left untreated. An unmet medical need is defined as the absence of an existing treatment or the availability of a potentially more effective treatment. Companies granted Fast Track status are able to have more frequent meetings and written communications with the FDA to discuss the drug's developmental plan, the design of proposed clinical trials and the use of biomarkers. This designation may also lead to faster drug approval.
Meeting An Unmet Need
With FAP, hundreds or thousands of precancerous polyps grow throughout the gastrointestinal tract. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. People with FAP, which usually appears in the patient's mid-teens, end up eventually having their entire colon removed.
There's a significant hereditary component to FAP, with a reported incidence of one in 5,000 to 10,000 in the U.S. and one in 11,300 to 37,600 in Europe. Biodexa, which has already received U.S. FDA Orphan Drug designation for eRapa in FAP, plans to seek a similar designation in Europe.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus, which slows down the mammalian Target Of Rapamycin (mTOR) protein. Too much mTOR has been linked to cancer and has been shown to be over-expressed in FAP polyps - thereby underscoring the rationale for using an mTOR inhibitor like eRapa to treat FAP. eRapa has a number of patents that the company says extend through 2035.
Promising Clinical Trials
It doesn't seem surprising that Biodexa received Fast Track designation for eRapa for FAP. Data from the company's phase 2 study of eRapa in FAP showed eRapa demonstrated a
"The promising phase 2 results, if confirmed in a registrational phase 3 study, may delay or potentially obviate the need for resection of the colon and/or rectum in FAP patients," said Stephen Stamp, CEO of Biodexa. "The six-month and 12-month data together with its apparent tolerability suggest longer-term use of eRapa may be possible, with the potential to forestall resection and substantially increase the quality of life of patients with this devastating precancerous condition impacting up to 40,000 patients in the U.S. and up to 60,000 in Europe."
People suffering from FAP deserve better options than screening and surgeries. Biodexa wants to deliver that with eRapa, and with the FDA Fast Track designation, it is getting closer to giving the thousands of people suffering from this precancerous disease a better alternative.
Featured photo by farland9 on stock.adobe.com.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Click here for more information on Biodexa Pharmaceuticals.
Contact:
Stephen Stamp, CEO, CFO
ir@biodexapharma.com
Important notice, please read: The information and statistical data contained herein may contain forward-looking statements that reflect the company's intentions, expectations, assumptions, or beliefs concerning future events, including, but not limited to, expectations with respect to FDA and other regulatory bodies approval of new products, technology, and product development milestones, the ability of the company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales, the size of market opportunities with respect to the company's product candidates and sufficiency of the company's cash flow for future liquidity and capital resource needs and other risks identified in the Risk Factor Section of the company's Annual Report and any subsequent reports filed with the SEC. We do not undertake to advise you as to any change in this information. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the company's research and development programs. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by Biodexa Pharmaceuticals PLC to provide investor relations services, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.
SOURCE: Biodexa Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What were the key results of BDRX's Phase 2 trial for eRapa?
How many patients will be enrolled in BDRX's Phase 3 trial for eRapa?
What is the market size for BDRX's FAP treatment?
How long does BDRX's patent protection for eRapa extend?
What benefits does FDA Fast Track status provide to BDRX?
